search
Back to results

The Role of Multimodality Imaging in Left Atrial Appendage Closure (MILAAC)

Primary Purpose

Atrial Fibrillation

Status
Recruiting
Phase
Not Applicable
Locations
Hungary
Study Type
Interventional
Intervention
Multimodal imaging
Standard imaging
Sponsored by
Hungarian Institute of Cardiology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Atrial Fibrillation focused on measuring atrial fibrillation, ischemic stroke, left atrial appendage closure, bleeding

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients, who have clinical indication to LAAC and are undergoing percutaneous LAAC procedure in Gottsegen National Cardiovascular Center from 10.03.2021 to 31.12.2025
  • Age above 18 years
  • Informed consent
  • Legal capacity

Exclusion Criteria:

  • Age under 18 years
  • Pregnancy
  • Incapacitation
  • Absence of consent
  • Esophageal stenosis or diverticulum
  • Active esophageal bleeding
  • CT-contrast agent allergy
  • Severe chronic kidney disease (GFR<15 ml/min/1,73 m2)
  • Appendage thrombus (mobile/with significant embolic risk)
  • Life expectancy shorter than 12 months
  • Active infection
  • Significant mitral valve stenosis
  • Mechanical heart valve
  • Open heart surgery is indicated

Sites / Locations

  • Hungarian Institute of Cardiology (Gottsegen National Cardiovascular Center)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Multimodal imaging

Standard imaging

Arm Description

Preoperative 2D/3D TOE AND MDCT for appendage characterisation and sizing Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)

Preoperative MDCT for appendage characterisation and sizing Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)

Outcomes

Primary Outcome Measures

Effective radiation dose
Total radiation dose of the patient resorbed during LAAC imaging and intervention (mSv)

Secondary Outcome Measures

Fluoroscopy time
during LAAC procedure (min)
Procedure time
of LAAC procedure (min)
Contrast media amount
used during LAAC procedure (ml)
Rate of successful implantations
left atrial appendage occluder successfully deployed and released
Rate of patients with adequate seal of closure device
Adequate seal defined as no leak or residual leak< 5 mm established by postoperative TOE
Rate of procedural complications
Thromboembolic events, myocardial infarction, bleeding events, vascular complications, pericardial effusion, tamponade, infections, allergic reactions, renal insufficiency, device/air embolism, mortality
Rate of clinical events
Composite endpoint of thromboembolic events (ischemic stroke, TIA, systemic embolism)

Full Information

First Posted
March 4, 2021
Last Updated
April 17, 2023
Sponsor
Hungarian Institute of Cardiology
search

1. Study Identification

Unique Protocol Identification Number
NCT04800913
Brief Title
The Role of Multimodality Imaging in Left Atrial Appendage Closure
Acronym
MILAAC
Official Title
The Role of Multimodality Imaging in Left Atrial Appendage Closure
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 8, 2021 (Actual)
Primary Completion Date
January 1, 2026 (Anticipated)
Study Completion Date
January 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hungarian Institute of Cardiology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the present prospective, randomized single-centre study is to examine the success rate, safety, overall preoperative and operative burden and long-time outcome of percutaneous left atrial appendage closure procedures after unimodal and multimodal preprocedural imaging. According to the investigators' primary hypothesis, simple, unimodal preprocedural imaging does not increase procedural burden of LAAC (total radiation dose, procedure time, fluoroscopy time, contrast amount). The investigators assume, that the success rate and safety of LAAC procedures is not reduced using unimodal preoperative imaging. Regarding to postoperative imaging, the investigators aim to compare the sensitivity of different imaging techniques in detecting postoperative complications. We assume, that multimodal imaging technique increases the accuracy and sensitivity of the detection of postoperative complications (PDL, device thrombi).
Detailed Description
Left atrial appendage closure (LAAC) is an increasingly used non-pharmacologic strategy to prevent stroke in patients with atrial fibrillation who have absolute or relative contraindications to long-term oral anticoagulant therapy, mainly due to previous major bleeding or high bleeding risk. As the majority of candidates are elderly patients with multiple morbidities, the reduction of procedural burden is of huge significance. The aim of the present prospective, randomized, single-centre study is to examine the non-inferiority of unimodal (MDCT) vs. multimodal (MDCT+TOE) preprocedural imaging in percutaneous left atrial appendage closure. The investigators are going to assess the success rate, safety and complications of LAAC procedures, and determine the procedural burden (total radiation dose, procedure time, fluoroscopy time, contrast amount) of the interventions after preprocedural unimodal and multimodal appendage characterization and device sizing. Multimodal procedural guidance (2D/3D TOE, fluoroscopy-angiography) and multimodal postprocedural imaging (2D/3D TOE, MDCT) is going to be used to identify complications (peri-device leak, thrombus). The investigators are planning to compare the accuracy and additive value of different postoperative imaging techniques. .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
atrial fibrillation, ischemic stroke, left atrial appendage closure, bleeding

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective randomized one-centre trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Multimodal imaging
Arm Type
Experimental
Arm Description
Preoperative 2D/3D TOE AND MDCT for appendage characterisation and sizing Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)
Arm Title
Standard imaging
Arm Type
Experimental
Arm Description
Preoperative MDCT for appendage characterisation and sizing Operative 2D/3D TOE and fluoroscopy/angiography for guiding and checking the procedural events and success Postoperative 2D/3D TOE and MDCT to assess the complications (peri-device leak, thrombus)
Intervention Type
Diagnostic Test
Intervention Name(s)
Multimodal imaging
Intervention Description
Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
Intervention Type
Diagnostic Test
Intervention Name(s)
Standard imaging
Intervention Description
Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
Primary Outcome Measure Information:
Title
Effective radiation dose
Description
Total radiation dose of the patient resorbed during LAAC imaging and intervention (mSv)
Time Frame
Periprocedural (1 month) interval
Secondary Outcome Measure Information:
Title
Fluoroscopy time
Description
during LAAC procedure (min)
Time Frame
during the procedure
Title
Procedure time
Description
of LAAC procedure (min)
Time Frame
during the procedure
Title
Contrast media amount
Description
used during LAAC procedure (ml)
Time Frame
during the procedure
Title
Rate of successful implantations
Description
left atrial appendage occluder successfully deployed and released
Time Frame
during the procedure
Title
Rate of patients with adequate seal of closure device
Description
Adequate seal defined as no leak or residual leak< 5 mm established by postoperative TOE
Time Frame
6 weeks post-procedure
Title
Rate of procedural complications
Description
Thromboembolic events, myocardial infarction, bleeding events, vascular complications, pericardial effusion, tamponade, infections, allergic reactions, renal insufficiency, device/air embolism, mortality
Time Frame
within 30 days post-procedure
Title
Rate of clinical events
Description
Composite endpoint of thromboembolic events (ischemic stroke, TIA, systemic embolism)
Time Frame
2 years post-procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients, who have clinical indication to LAAC and are undergoing percutaneous LAAC procedure in Gottsegen National Cardiovascular Center from 10.03.2021 to 31.12.2025 Age above 18 years Informed consent Legal capacity Exclusion Criteria: Age under 18 years Pregnancy Incapacitation Absence of consent Esophageal stenosis or diverticulum Active esophageal bleeding CT-contrast agent allergy Severe chronic kidney disease (GFR<15 ml/min/1,73 m2) Appendage thrombus (mobile/with significant embolic risk) Life expectancy shorter than 12 months Active infection Significant mitral valve stenosis Mechanical heart valve Open heart surgery is indicated
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peter Andreka, MD, PhD
Phone
0036703820470
Email
peter.andreka@gokvi.hu
First Name & Middle Initial & Last Name or Official Title & Degree
Geza Fontos, MD
Phone
0036703820358
Email
geza.fontos@gokvi.hu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anita Zadori, MD, PhD
Organizational Affiliation
0036303837011, anita.zadori@gokvi.hu
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hungarian Institute of Cardiology (Gottsegen National Cardiovascular Center)
City
Budapest
ZIP/Postal Code
1096
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anita Zadori, MD, PhD
Phone
0036303837011
Email
anita.zadori@gokvi.hu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27567408
Citation
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27. No abstract available.
Results Reference
background
PubMed Identifier
29103847
Citation
Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr; PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975. doi: 10.1016/j.jacc.2017.10.021. Epub 2017 Nov 4.
Results Reference
background
PubMed Identifier
27979034
Citation
Osmancik P, Tousek P, Herman D, Neuzil P, Hala P, Stasek J, Haman L, Kala P, Poloczek M, Branny M, Chovancik J, Cervinka P, Holy J, Vancura V, Rokyta R, Taborsky M, Kovarnik T, Zemanek D, Peichl P, Haskova S, Jarkovsky J, Widimsky P; PRAGUE-17 Investigators. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study). Am Heart J. 2017 Jan;183:108-114. doi: 10.1016/j.ahj.2016.10.003. Epub 2016 Oct 11.
Results Reference
background
PubMed Identifier
21737601
Citation
Nucifora G, Faletra FF, Regoli F, Pasotti E, Pedrazzini G, Moccetti T, Auricchio A. Evaluation of the left atrial appendage with real-time 3-dimensional transesophageal echocardiography: implications for catheter-based left atrial appendage closure. Circ Cardiovasc Imaging. 2011 Sep;4(5):514-23. doi: 10.1161/CIRCIMAGING.111.963892. Epub 2011 Jul 7.
Results Reference
background
PubMed Identifier
28013284
Citation
Rajwani A, Nelson AJ, Shirazi MG, Disney PJS, Teo KSL, Wong DTL, Young GD, Worthley SG. CT sizing for left atrial appendage closure is associated with favourable outcomes for procedural safety. Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1361-1368. doi: 10.1093/ehjci/jew212.
Results Reference
background
PubMed Identifier
11997272
Citation
Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Della Bella P, Nakai T, Reisman M, DiMario C, Block P, Kramer P, Fleschenberg D, Krumsdorf U, Scherer D. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002 Apr 23;105(16):1887-9. doi: 10.1161/01.cir.0000015698.54752.6d.
Results Reference
background
PubMed Identifier
31217149
Citation
Qamar SR, Jalal S, Nicolaou S, Tsang M, Gilhofer T, Saw J. Comparison of cardiac computed tomography angiography and transoesophageal echocardiography for device surveillance after left atrial appendage closure. EuroIntervention. 2019 Oct 20;15(8):663-670. doi: 10.4244/EIJ-D-18-01107.
Results Reference
background

Learn more about this trial

The Role of Multimodality Imaging in Left Atrial Appendage Closure

We'll reach out to this number within 24 hrs